Financial comparisons Celltrion, Inc.
Equities
A068270
KR7068270008
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
181,000.00 KRW | +1.51% |
|
+0.44% | -3.47% |
Feb. 04 | South Korean Shares Rally on US Tariff Delay; Celltrion Shares Rise 1% on FDA Approval for ACTEMRA Biosimilar | MT |
Feb. 03 | Celltrion Secures FDA Approval for AVTOZMA Tocilizumab Biosimilar | MT |
Revenues (Y-1) | Net margin (Y-1) | EBIT margin (Y-1) | ROE (Y-1) | ROA (Y-1) | Leverage (Y-1) | ||
---|---|---|---|---|---|---|---|
1.68B | 24.61% | 29.93% | 5.07% | 4.31% | 1.46x | ||
7.98B | 9.74% | 13.98% | 6.52% | 3.82% | 0.46x | ||
14.98B | 9.06% | 20.36% | 32.01% | 5.22% | 3.45x | ||
8.12B | 7.54% | 19.31% | 6.9% | 3.58% | 2x | ||
2.33B | 42.31% | 50.91% | 18.27% | 14.91% | -1.85x | ||
6.85B | 68.84% | 61.9% | 28.59% | 21.29% | 2.38x | ||
1.16B | 14.5% | 31.94% | 14.11% | 6.29% | 0.4x | ||
1.89B | 15% | 17.94% | 59.83% | 18.8% | -0.29x | ||
532M | 40.26% | - | - | - | - | ||
1.97B | 17.37% | 26.9% | 4.69% | 2.75% | 0.69x | ||
4.13B | 11.49% | 20.31% | 16.7% | 6.95% | 2.34x | ||
11.58M | 3,768.28% | 4,207.12% | 34.76% | 30.38% | 3.85x | ||
249M | 203.3% | 194.99% | 157.13% | - | 0.99x | ||
343M | 1.04% | 10.29% | 34.35% | 12.03% | -1.95x | ||
1.63B | 13.88% | 14.92% | 13.86% | 6.82% | 1.36x | ||
1.04B | 27.44% | 35.35% | 9.95% | 7.09% | -1.51x | ||
788M | 46.45% | 44.8% | 76.34% | 13.26% | 3.21x | ||
1.66B | 21.39% | 24.9% | 21.69% | 11.88% | -1.07x | ||
234M | 5.42% | 8.83% | 11.57% | 4.84% | -5.63x | ||
Average | 3.03B | percentage-no-prefix | percentage-no-prefix | percentage-no-prefix | percentage-no-prefix | 0.57x | |
Weighted average by Cap. | 5.4B | percentage-no-prefix | percentage-no-prefix | percentage-no-prefix | percentage-no-prefix | 1.07x |
- Stock Market
- Equities
- A068270 Stock
- Sector Celltrion, Inc.
- Financial comparisons